1CC0
 
 | | CRYSTAL STRUCTURE OF THE RHOA.GDP-RHOGDI COMPLEX | | 分子名称: | GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, rho GDP dissociation inhibitor alpha, ... | | 著者 | Longenecker, K.L, Read, P, Derewenda, U, Dauter, Z, Garrard, S, Walker, L, Somlyo, A.V, Somlyo, A.P, Nakamoto, R.K, Derewenda, Z.S. | | 登録日 | 1999-03-03 | | 公開日 | 2000-01-07 | | 最終更新日 | 2023-12-27 | | 実験手法 | X-RAY DIFFRACTION (5 Å) | | 主引用文献 | How RhoGDI binds Rho.
Acta Crystallogr.,Sect.D, 55, 1999
|
|
5MJY
 | |
5MK1
 | |
5MJZ
 | |
5MK3
 | |
5MK0
 | |
5MK2
 | |
5K59
 | | Crystal structure of LukGH from Staphylococcus aureus in complex with a neutralising antibody | | 分子名称: | CHLORIDE ION, Fab heavy chain, Fab light chain, ... | | 著者 | Welin, M, Logan, D.T, Badarau, A, Mirkina, I, Zauner, G, Dolezilkova, I, Nagy, E. | | 登録日 | 2016-05-23 | | 公開日 | 2016-08-10 | | 最終更新日 | 2018-01-17 | | 実験手法 | X-RAY DIFFRACTION (2.84 Å) | | 主引用文献 | Context matters: The importance of dimerization-induced conformation of the LukGH leukocidin of Staphylococcus aureus for the generation of neutralizing antibodies.
Mabs, 8, 2016
|
|
6ND2
 | | Staphylococcus aureus Dihydrofolate Reductase complexed with NADPH and 6-ETHYL-5-[(3R)-3-[2-METHOXY-5-(PYRIDIN-4-YL)PHENYL]BUT-1-YN-1-YL]PYRIMIDINE-2,4-DIAMINE (UCP1063) | | 分子名称: | 6-ethyl-5-{(3S)-3-[2-methoxy-5-(pyridin-4-yl)phenyl]but-1-yn-1-yl}pyrimidine-2,4-diamine, Dihydrofolate reductase, GLYCEROL, ... | | 著者 | Reeve, S.M, Wright, D.L. | | 登録日 | 2018-12-13 | | 公開日 | 2019-09-25 | | 最終更新日 | 2023-10-11 | | 実験手法 | X-RAY DIFFRACTION (2.243 Å) | | 主引用文献 | Structure-Guided In Vitro to In Vivo Pharmacokinetic Optimization of Propargyl-Linked Antifolates.
Drug Metab.Dispos., 47, 2019
|
|
3COH
 | | Crystal structure of Aurora-A in complex with a pentacyclic inhibitor | | 分子名称: | 8-ethyl-3,10,10-trimethyl-4,5,6,8,10,12-hexahydropyrazolo[4',3':6,7]cyclohepta[1,2-b]pyrrolo[2,3-f]indol-9(1H)-one, Serine/threonine-protein kinase 6 | | 著者 | Wiesmann, C, Raswson, T.E, Cochran, A.G. | | 登録日 | 2008-03-28 | | 公開日 | 2009-02-17 | | 最終更新日 | 2023-08-30 | | 実験手法 | X-RAY DIFFRACTION (2.7 Å) | | 主引用文献 | A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability.
J.Med.Chem., 51, 2008
|
|
3H0Z
 | | Aurora A in complex with a bisanilinopyrimidine | | 分子名称: | 4-{[2-({4-[2-(4-acetylpiperazin-1-yl)-2-oxoethyl]phenyl}amino)-5-fluoropyrimidin-4-yl]amino}-N-(2-chlorophenyl)benzamide, Serine/threonine-protein kinase 6 | | 著者 | Wiesmann, C, Ultsch, M.H, Cochran, A.G. | | 登録日 | 2009-04-10 | | 公開日 | 2009-07-07 | | 最終更新日 | 2024-02-21 | | 実験手法 | X-RAY DIFFRACTION (2.92 Å) | | 主引用文献 | A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.
J.Med.Chem., 52, 2009
|
|
3H10
 | | Aurora A inhibitor complex | | 分子名称: | 9-chloro-7-(2,6-difluorophenyl)-N-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine, Serine/threonine-protein kinase 6 | | 著者 | Wiesmann, C, Ultsch, M.H, Cochran, A.G. | | 登録日 | 2009-04-10 | | 公開日 | 2009-07-07 | | 最終更新日 | 2024-02-21 | | 実験手法 | X-RAY DIFFRACTION (2.2 Å) | | 主引用文献 | A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.
J.Med.Chem., 52, 2009
|
|
3H0Y
 | | Aurora A in complex with a bisanilinopyrimidine | | 分子名称: | 2-chloro-N-[4-({5-fluoro-2-[(4-hydroxyphenyl)amino]pyrimidin-4-yl}amino)phenyl]benzamide, SULFATE ION, Serine/threonine-protein kinase 6 | | 著者 | Wiesmann, C, Ultsch, M.H, Cochran, A.G. | | 登録日 | 2009-04-10 | | 公開日 | 2009-07-07 | | 最終更新日 | 2024-02-21 | | 実験手法 | X-RAY DIFFRACTION (2.5 Å) | | 主引用文献 | A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.
J.Med.Chem., 52, 2009
|
|
